EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Sorafenib enforces HIV-1 latency by selectively inhibiting PKC-driven STAT1/3 serine 727 phosphorylation

Peipei Wang, Zhuoyue Meng, Jiasheng Zhou, Huixin Wu, Wei Wang, Zhiliang Gao iD, Ying Zhang iD, Jinfeng Cai iD

Antimicrobial Agents and Chemotherapy · 2026

DOI: 10.1128/aac.00540-26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Peipei Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. Hauptthemen laut MEDLINE: STAT1 Transcription Factor, HIV-1, STAT3 Transcription Factor, Virus Latency. Die Arbeit nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China (NSFC).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Eliminating the latent HIV-1 reservoir remains a major barrier to achieving a functional cure. The “block-and-lock” strategy aims to enforce durable transcriptional silencing of proviruses, thereby preventing viral rebound upon interruption of antiretroviral therapy. However, the molecular mechanisms governing stable latency remain incompletely understood. Here, we identify protein kinase C (PKC)-dependent phosphorylation of STAT1 and STAT3 at serine 727 as a previously unrecognized regulatory checkpoint controlling HIV-1 transcriptional reactivation. Pharmacological inhibition of this axis using sorafenib, a clinically approved multi-kinase inhibitor, robustly suppresses HIV-1 reactivation across multiple latency models and promotes the establishment of latency in primary CD4 + T cells. Mechanistically, sorafenib attenuates phorbol 12-myristate 13-acetate (PMA)-induced activation of the JAK-STAT and PI3K-Akt signaling pathways, and selectively blocks PKC-mediated phosphorylation of STAT1/3 at serine 727 without affecting canonical tyrosine phosphorylation (Y701/Y705). This selective inhibition disrupts transcriptional activation at the HIV-1 long terminal repeat ( LTR ), thereby preventing viral reactivation. Importantly, sorafenib does not induce detectable cytotoxicity or alter activation and exhaustion markers in primary CD4 + T cells, supporting a favorable safety profile in vitro . Collectively, our findings define a critical role for STAT1/3 Ser727 in the regulation of HIV-1 latency and establish sorafenib as a promising latency-promoting agent for future applications in the development of a functional cure for HIV-1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

STAT1 Transcription FactorHIV-1STAT3 Transcription FactorVirus LatencyProtein Kinase CSorafenibHumansPhosphorylationCD4-Positive T-LymphocytesSerineSignal TransductionVirus ActivationTetradecanoylphorbol AcetateHIV Long Terminal Repeat

Stichwörter der Autor:innen

HIV-1STAT1/3 Ser727latency-promoting agentsorafenib

Substanzen

STAT1 Transcription FactorSTAT3 Transcription FactorProtein Kinase CSorafenibSerineSTAT1 protein, humanSTAT3 protein, humanTetradecanoylphorbol Acetate

Autor:innen und Institutionen

  • Department of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
  • Institute of Human Virology, Key Laboratory of Tropical Disease Control of Ministry of Education, Zhongshan School of Medicine of Sun Yat-sen University, Guangzhou, China.
  • Department of Immunology and Microbiology, Zhongshan School of Medicine of Sun Yat-sen University, Guangzhou, China.
  • National Engineering Technology Research Center for Combined Vaccines, Wuhan, China.

ORCID-Profile: Zhiliang Gao, Ying Zhang, Jinfeng Cai

Förderung

  • National Natural Science Foundation of China (NSFC)

Zitieren

APA

Wang, P., Meng, Z., Zhou, J., Wu, H., Wang, W., Gao, Z., Zhang, Y., & Cai, J. (2026). Sorafenib enforces HIV-1 latency by selectively inhibiting PKC-driven STAT1/3 serine 727 phosphorylation. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00540-26

Vancouver

Wang P, Meng Z, Zhou J, Wu H, Wang W, Gao Z, et al. Sorafenib enforces HIV-1 latency by selectively inhibiting PKC-driven STAT1/3 serine 727 phosphorylation. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.00540-26

BibTeX
@article{Wang2026,
  author = {Wang, Peipei and Meng, Zhuoyue and Zhou, Jiasheng and Wu, Huixin and Wang, Wei and Gao, Zhiliang and Zhang, Ying and Cai, Jinfeng},
  title = {Sorafenib enforces HIV-1 latency by selectively inhibiting PKC-driven STAT1/3 serine 727 phosphorylation},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  doi = {10.1128/aac.00540-26}
}
Kostenlos starten →